{"id":"atovaquone-proguanil-and-artesunate-pyronaridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atovaquone-proguanil works by disrupting the electron transport chain in Plasmodium mitochondria and inhibiting dihydrofolate reductase, while artesunate-pyronaridine acts through artemisinin-derived endoperoxide activation and quinoline-like mechanisms to damage parasite proteins and DNA. The combination provides synergistic activity against both drug-sensitive and drug-resistant malaria parasites across multiple life-cycle stages.","oneSentence":"This combination drug uses atovaquone-proguanil to inhibit parasite mitochondrial function and pyronaridine-artesunate to generate reactive oxygen species and inhibit heme polymerization, together targeting multiple stages of malaria parasite development.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:57.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (Plasmodium falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi)"}]},"trialDetails":[{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atovaquone Proguanil and Artesunate Pyronaridine","genericName":"Atovaquone Proguanil and Artesunate Pyronaridine","companyName":"Armed Forces Research Institute of Medical Sciences, Thailand","companyId":"armed-forces-research-institute-of-medical-sciences-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug uses atovaquone-proguanil to inhibit parasite mitochondrial function and pyronaridine-artesunate to generate reactive oxygen species and inhibit heme polymerization, together targeting multiple stages of malaria parasite development. Used for Malaria (Plasmodium falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}